The Truth about Metabolic Surgery
Thursday, July 3, 2014
Some authors suggest that bariatric surgery is the best treatment for type 2 Diabetes in morbid and non-morbid obese patients. Up to 17 world-renowned doctors and surgeons, among which are Antonio M. Lacy, Francesco Rubino, Philip R. Schauer and Josep Vidal, reviewed the effectiveness of bariatric surgery on type 2 Diabetes patients in this live streaming conference.
AIS Channel, in association with the Hospital Clínic of Barcelona, brought together world leading professionals in endocrinology and metabolic surgery to analyze the effectiveness of bariatric surgery to treat the Type 2 Diabetes and the durability of its benefits.
During the 5th AIS Channel congress The Truth About Metabolic Surgery, a live streaming sleeve gastrectomy surgery was performed by Dr. Antonio M. Lacy and Dr. Salvadora Delgado. Commentary throughout the operation by doctors Ricard Corcelles, Michel Gagner, Marta Jiménez and Josep Vidal.
The 5th AIS Congress on the Truth of Metabolic Surgery clearly showed the agreement between endocrinologists and surgeons on that metabolic surgery deserves being part of the therapeutic armamentarium of type 2 diabetes.
As reviewed by Dr. Schauer, studies have overwhelmingly demonstrated metabolic surgery is superior to the best medical therapy in helping obese patients with type 2 diabetes to achieve metabolic goals. Thus, as Dr. Rubino nicely pointed out, it is now time to implement metabolic surgery in our model of care for this increasingly common disease.
This will entail moving away from the weight-centric model characteristic of bariatric surgery, to a disease-centric model in which the characterization of the surgical candidates and goal-setting will require close collaboration between the different professionals involved in diabetes care.
A panel of world renowned surgeons in the field of metabolic surgery agreed that one size does not fit all when it comes to consider which surgical technique is best for a particular diabetic patient. They agreed current surgical techniques are very effective for the control of type 2 diabetes. However, further collaboration among health professionals involved in metabolic surgery is warranted to develop a staging system that could help best tailor the surgical techniques to a particular patient.
Finally, endocrinologists working in the field of metabolic surgery discussed the latest advances in the understanding of the mechanisms that ensure the clinical benefits of metabolic surgery. Undoubtedly, the ultimate goal of this research would be to translate this knowledge into new venues for medical therapy. As discussed by Dr. Le Roux, this would result in a knifeless-surgery approach in which the patient would be treated with combination of medical therapies derived from our understanding on those mechanisms.
The panel of experts participating in the 5th AIS Congress expressed hope on that this may happen sometime along the way. Nonetheless, at the same time they strongly urged to abate the barriers preventing the integration of metabolic surgery to our daily practice in the care of obese subjects with type 2 diabetes.